Current Report Filing (8-k)
December 03 2019 - 9:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 3, 2019
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36279
|
|
75-3175693
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
4 Stamford Plaza
107 Elm Street, 9th Floor
Stamford, Connecticut
|
|
|
|
06902
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrant's telephone number, including area code: (203) 406-3700
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2.):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
CARA
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. x
|
Item 7.01
|
Regulation FD Disclosure.
|
On December
3, 2019, Cara Therapeutics, Inc. (the “Company”) issued a press release and held a conference call announcing
top-line data from its Phase 2 clinical trial of Oral KORSUVA for chronic kidney disease-associated pruritus
(“CKD-aP”). A copy of the press release and the presentation discussed on the conference call are furnished as
Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.
The information
furnished under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall
not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company,
regardless of any general incorporation language in such filing.
|
Item 8.01
|
Other
Information.
|
On December 3, 2019, the Company issued
a press release announcing top-line data from its Phase 2 clinical trial of Oral KORSUVA for CKD-aP.
The Phase 2, multicenter, randomized, double-blind,
placebo-controlled 12-week trial was designed to evaluate the safety and efficacy of three tablet strengths (0.25 mg, 0.5 mg
and 1 mg, once daily administration) of Oral KORSUVA versus placebo in approximately 240 stage III-V (moderate to severe) CKD patients
with moderate-to-severe pruritus. The primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour
worst itch Numeric Rating Scale (“WI-NRS”) score at Week 12 of the treatment period. Secondary endpoints included change
from baseline in itch-related quality of life scores at the end of Week 12, as assessed by the total Skindex-10 and 5-D
itch scores, as well as the proportion of patients achieving an improvement from baseline ≥3 points with respect to the weekly
mean of the daily 24-hour WI-NRS score at Week 12.
Primary Endpoint: Patients treated
with the 1 mg once daily tablet strength of Oral KORSUVA achieved the primary endpoint of statistically significant reduction in
weekly mean of the daily WI-NRS scores versus placebo after the 12-week treatment period (-4.4 KORSUVA vs. -3.3 placebo, p=0.018).
The treatment effect was statistically significant after 2 weeks of treatment and sustained through the 12-week treatment period.
Secondary Endpoints:
Proportion of Responders. The proportion
of patients on 1 mg tablet strength achieving a 3 point or greater improvement from baseline in the weekly mean of the daily WI-NRS
score at Week 12 was 72% versus 58% for patients on placebo but did not achieve statistical significance.
Itch-Related Quality of Life Measures.
Patients on Oral KORSUVA showed dose-related improvements vs. placebo in itch-related quality of life endpoints as measured using
self-assessment Skindex-10 and 5-D Itch scales but did not achieve statistical significance.
Safety and Tolerability: Oral KORSUVA
was generally well tolerated with a safety profile consistent with that seen in earlier KORSUVA clinical trials. Overall, the incidence
of treatment-emergent adverse events (“AEs”) were similar across KORSUVA and placebo groups. The most common treatment-emergent
AEs reported in >5% of patients in the 1 mg KORSUVA group versus placebo were dizziness (7.5% KORSUVA vs. 0% placebo), fall
(6% KORSUVA vs. 0% placebo), diarrhea (6% KORSUVA vs. 1.5% placebo) and constipation (KORSUVA 6% vs. 3% placebo).
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CARA THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Mani Mohindru
|
|
|
Mani Mohindru, Ph.D.
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial and Accounting Officer)
|
Date: December 3, 2019
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024